Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Green tea extract for prevention of prostate cancer progression in patients on active surveillance.

Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J.

Oncotarget. 2018 Dec 28;9(102):37798-37806. doi: 10.18632/oncotarget.26519. eCollection 2018 Dec 28. Review.

2.

Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors.

Parra AN, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y.

Oncotarget. 2018 Dec 14;9(98):37125-37136. doi: 10.18632/oncotarget.26437. eCollection 2018 Dec 14.

3.

Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov 9. doi: 10.1158/1055-9965.EPI-18-0812. [Epub ahead of print]

PMID:
30413401
4.

Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center.

Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY.

BMC Anesthesiol. 2018 Nov 3;18(1):157. doi: 10.1186/s12871-018-0622-5.

5.

Prostate cancer mortality rates in Peru and its geographical regions.

Torres-Roman JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, Taxa L, Saldaña-Gallo J, Pow-Sang MR, Pow-Sang JM, La Vecchia C.

BJU Int. 2018 Oct 3. doi: 10.1111/bju.14578. [Epub ahead of print]

PMID:
30281883
6.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

7.

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM.

JAMA Oncol. 2018 Nov 1;4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542.

PMID:
30178038
8.

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.

Azizi M, Peyton CC, Boulware DC, Chipollini J, Juwono T, Pow-Sang JM, Spiess PE.

Eur Urol Focus. 2018 Jun 21. pii: S2405-4569(18)30156-1. doi: 10.1016/j.euf.2018.06.008. [Epub ahead of print]

PMID:
29937330
9.

AA9int: SNP interaction pattern search using non-hierarchical additive model set.

Lin HY, Huang PY, Chen DT, Tung HY, Sellers TA, Pow-Sang JM, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Neal DE, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ; PRACTICAL Consortium, Park JY.

Bioinformatics. 2018 Dec 15;34(24):4141-4150. doi: 10.1093/bioinformatics/bty461.

PMID:
29878078
10.

Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience.

Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ.

Clin Genitourin Cancer. 2018 Oct;16(5):e1003-e1013. doi: 10.1016/j.clgc.2018.05.012. Epub 2018 May 18.

PMID:
29859736
11.

African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015.

Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K.

Cancer Med. 2018 May;7(5):2160-2171. doi: 10.1002/cam4.1451. Epub 2018 Mar 30.

12.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ.

Oncotarget. 2017 Jun 29;8(58):99093-99103. doi: 10.18632/oncotarget.18858. eCollection 2017 Nov 17.

13.

Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer.

Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE.

Urol Oncol. 2018 Jan;36(1):14.e1-14.e5. doi: 10.1016/j.urolonc.2017.08.018. Epub 2017 Oct 9.

PMID:
29032883
14.

Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer.

Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE.

J Urol. 2017 Dec;198(6):1346-1352. doi: 10.1016/j.juro.2017.06.076. Epub 2017 Jun 23.

PMID:
28652123
15.

Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?

Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE.

Clin Genitourin Cancer. 2017 Dec;15(6):696-703. doi: 10.1016/j.clgc.2017.05.011. Epub 2017 May 10.

PMID:
28566202
16.

Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center.

Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 Jul;105:108-112. doi: 10.1016/j.urology.2017.03.023. Epub 2017 Mar 23.

PMID:
28342928
17.

Author Reply.

Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 May;103:148. doi: 10.1016/j.urology.2016.12.017. Epub 2017 Jan 17. No abstract available.

PMID:
28108090
18.

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.

Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ.

Oncotarget. 2016 Oct 25;7(43):70794-70802. doi: 10.18632/oncotarget.12222.

19.

SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns.

Lin HY, Chen DT, Huang PY, Liu YH, Ochoa A, Zabaleta J, Mercante DE, Fang Z, Sellers TA, Pow-Sang JM, Cheng CH, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ; PRACTICAL Consortium, Park JY.

Bioinformatics. 2017 Mar 15;33(6):822-833. doi: 10.1093/bioinformatics/btw762.

20.

Biomarkers for prostate cancer: present challenges and future opportunities.

Sharma P, Zargar-Shoshtari K, Pow-Sang JM.

Future Sci OA. 2015 Dec 17;2(1):FSO72. doi: 10.4155/fso.15.72. eCollection 2016 Mar. Review.

21.

Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival.

Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA.

Urology. 2017 May;103:142-148. doi: 10.1016/j.urology.2016.12.015. Epub 2016 Dec 21.

PMID:
28011275
22.

Chemoprevention in African American Men With Prostate Cancer.

Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM.

Cancer Control. 2016 Oct;23(4):415-423.

PMID:
27842331
23.

Geographical Factors Associated With Health Disparities in Prostate Cancer.

Gilbert SM, Pow-Sang JM, Xiao H.

Cancer Control. 2016 Oct;23(4):401-408.

PMID:
27842329
24.

Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis.

Zargar H, Lamb AD, Rocco B, Porpiglia F, Liatsikos E, Davis J, Coelho RF, Pow-Sang JM, Patel VR, Murphy DG.

Minerva Urol Nefrol. 2017 Feb;69(1):26-37. Epub 2016 Aug 31.

25.

Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?

Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM.

World J Urol. 2017 Apr;35(4):657-663. doi: 10.1007/s00345-016-1915-2. Epub 2016 Aug 5.

PMID:
27495912
26.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network; PRACTICAL consortium, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D.

Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.

27.

Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.

Cook LM, Araujo A, Pow-Sang JM, Budzevich MM, Basanta D, Lynch CC.

Sci Rep. 2016 Jul 14;6:29384. doi: 10.1038/srep29384.

28.

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.

Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB.

Clin Cancer Res. 2016 Nov 15;22(22):5605-5616. doi: 10.1158/1078-0432.CCR-15-1673. Epub 2016 May 24.

29.

Long term survival and predictors of disease reclassification in patients on an active surveillance protocol for prostate cancer.

Agarwal G, Buethe D, Russell C, Luchey A, Pow-Sang JM.

Can J Urol. 2016 Apr;23(2):8215-9.

PMID:
27085826
30.

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ.

World J Urol. 2016 Nov;34(11):1567-1573. Epub 2016 Apr 12.

PMID:
27072536
31.

Letter From the Editors: A New Step Rather Than a New Era.

Balducci L, Pow-Sang JM.

Cancer Control. 2015 Oct;22(4):381. No abstract available.

PMID:
27062729
32.

Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice.

Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA.

Urology. 2016 Jul;93:130-4. doi: 10.1016/j.urology.2016.01.048. Epub 2016 Mar 31.

PMID:
27041469
33.

Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?

Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ.

Can J Urol. 2016 Feb;23(1):8127-34.

PMID:
26892052
34.

Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy.

Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS.

J Am Coll Surg. 2016 Apr;222(4):702-9. doi: 10.1016/j.jamcollsurg.2015.12.033. Epub 2016 Jan 14.

35.

Urology residents experience comparable workload profiles when performing live porcine nephrectomies and robotic surgery virtual reality training modules.

Mouraviev V, Klein M, Schommer E, Thiel DD, Samavedi S, Kumar A, Leveillee RJ, Thomas R, Pow-Sang JM, Su LM, Mui E, Smith R, Patel V.

J Robot Surg. 2016 Mar;10(1):49-56. doi: 10.1007/s11701-015-0540-1. Epub 2016 Jan 11.

PMID:
26753619
36.

Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

PMID:
26733552
37.

Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy.

Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE.

Int Braz J Urol. 2015 Sep-Oct;41(5):911-9. doi: 10.1590/S1677-5538.IBJU.2014.0371.

38.

Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.

Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M.

Urol Oncol. 2016 Mar;34(3):122.e1-7. doi: 10.1016/j.urolonc.2015.09.015. Epub 2015 Nov 3.

39.

Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis.

Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE.

Clin Genitourin Cancer. 2016 Feb;14(1):89-95. doi: 10.1016/j.clgc.2015.09.007. Epub 2015 Sep 25.

PMID:
26453395
40.

Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.

Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ.

Clin Genitourin Cancer. 2016 Feb;14(1):82-8. doi: 10.1016/j.clgc.2015.08.006. Epub 2015 Aug 29.

PMID:
26411593
41.

Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes.

Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE.

ANZ J Surg. 2016 Jan-Feb;86(1-2):44-8. doi: 10.1111/ans.13272. Epub 2015 Sep 15.

PMID:
26370725
42.

Robotic-Assisted Laparoscopic Radical Prostatectomy.

Agarwal G, Valderrama O, Luchey AM, Pow-Sang JM.

Cancer Control. 2015 Jul;22(3):283-90. Review.

PMID:
26351883
43.

Applications and Advances in Robotic-Assisted Oncological Surgery: Ready to Dock the 'Bot.

Toloza EM, Pow-Sang JM.

Cancer Control. 2015 Jul;22(3):278-9. No abstract available.

PMID:
26351882
44.

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.

Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM.

Can J Urol. 2015 Aug;22(4):7882-9.

PMID:
26267026
45.

Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy.

Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM.

J Urol. 2016 Jan;195(1):47-52. doi: 10.1016/j.juro.2015.07.095. Epub 2015 Jul 31.

46.

Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs.

Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ.

Urology. 2015 Aug;86(2):321-6. doi: 10.1016/j.urology.2015.05.013. Epub 2015 Jul 15.

PMID:
26187013
47.

Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE.

Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18.

PMID:
26094169
48.

An extramedullary plasmacytoma in the testicle: A case report and review of the literature.

Lue K, Emtage JB, Pariñas MA, Dhillon J, Pow-Sang J.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E240-2. doi: 10.5489/cuaj.2531.

49.

Colorectal Cancer: The Last Nail in the Coffin for Androgen Deprivation Therapy for Prostate Cancer?

Balducci L, Pow-Sang JM.

Cancer Control. 2015 Apr;22(2):259-60. No abstract available.

PMID:
26068774
50.

Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population.

Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ.

J Endourol. 2015 Oct;29(10):1193-8. doi: 10.1089/end.2014.0881. Epub 2015 Jul 13.

PMID:
26058496

Supplemental Content

Loading ...
Support Center